相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Aurora Kinase A Inhibition Leads to p73-Dependent Apoptosis in p53-Deficient Cancer Cells
Altaf A. Dar et al.
CANCER RESEARCH (2008)
DNA damage detection and repair pathways - Recent advances with inhibitors of checkpoint kinases in cancer therapy
Susan Ashwell et al.
CLINICAL CANCER RESEARCH (2008)
Polo and Aurora kinases - lessons derived from chemical biology
Stephen Taylor et al.
CURRENT OPINION IN CELL BIOLOGY (2008)
The MDM2 inhibitor nutlins as an innovative therapeutic tool for the treatment of haematological malignancies
Paola Secchiero et al.
CURRENT PHARMACEUTICAL DESIGN (2008)
Phase I Dose Escalation and Pharmacokinetic Study of BI 2536, a Novel Polo-Like Kinase 1 Inhibitor, in Patients With Advanced Solid Tumors
Klaus Mross et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Kinase requirements in human cells: I. Comparing kinase requirements across various cell types
Dorre A. Grueneberg et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Core signaling pathways in human pancreatic cancers revealed by global genomic analyses
Sian Jones et al.
SCIENCE (2008)
An integrated genomic analysis of human glioblastoma Multiforme
D. Williams Parsons et al.
SCIENCE (2008)
The genomic landscapes of human breast and colorectal cancers
Laura D. Wood et al.
SCIENCE (2007)
Shaping genetic alterations in human cancer: The p53 mutation paradigm
Thierry Soussi et al.
CANCER CELL (2007)
The codon 72 polymorphism-specific effects of human p53 are absent in mouse cells:: implications on generation of mouse models
B. H. Phang et al.
ONCOGENE (2007)
The small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of polo-like kinase 1
Peter Lenart et al.
CURRENT BIOLOGY (2007)
BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo
Martin Steegmaier et al.
CURRENT BIOLOGY (2007)
p53 in health and disease
Karen H. Vousden et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2007)
The consensus coding sequences of human breast and colorectal cancers
Tobias Sjoeblom et al.
SCIENCE (2006)
Strategies for therapeutic targeting of the p53 pathway in cancer
K. G. Wiman
CELL DEATH AND DIFFERENTIATION (2006)
Transcriptional regulation by p53: one protein, many possibilities
O. Laptenko et al.
CELL DEATH AND DIFFERENTIATION (2006)
Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analogs
VJN Bykov et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
In vivo activation of the p53 pathway by small-molecule antagonists of MDM2
LT Vassilev et al.
SCIENCE (2004)
被撤回的出版物: Transactivation of the EGR1 gene contributes to mutant p53 gain of function (Retracted article. See vol. 79, pg. 2085, 2019)
L Weisz et al.
CANCER RESEARCH (2004)
Comparison of the effect of mutant and wild-type p53 on global gene expression
TJ O'Farrell et al.
CANCER RESEARCH (2004)
Modulation of gene expression by tumor-derived p53 mutants
MJ Scian et al.
CANCER RESEARCH (2004)
Isolation of p53-target genes and their functional analysis
Y Nakamura
CANCER SCIENCE (2004)
Decision making by p53: life, death and cancer
M Oren
CELL DEATH AND DIFFERENTIATION (2003)
Identification of unknown target genes of human transcription factors using chromatin immunoprecipitation
AS Weinmann et al.
METHODS (2002)
The IARC TP53 database: New Online mutation analysis and recommendations to users
M Olivier et al.
HUMAN MUTATION (2002)
Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound
VJN Bykov et al.
NATURE MEDICINE (2002)
ATR inhibition selectively sensitizes G1 checkpoint-deficient cells to lethal premature chromatin condensation
P Nghiem et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Cellular senescence as a tumor-protection mechanism: the essential role of counting
WE Wright et al.
CURRENT OPINION IN GENETICS & DEVELOPMENT (2001)